The SINUVA Sinus Implant is a steroid-releasing (mometasone furoate) implant indicated for the treatment of nasal polyps. SINUVA may be an alternative to sinus surgery and other treatment options.
SINUVA is an innovative technology that reduces polyps and the sensation of nasal congestion and obstruction with a 2-in-1 approach:
The SINUVA Sinus Implant was introduced as an additional therapy option for patients who had recurring nasal polyps after sinus surgery. SINUVA helps patients to
SINUVA is placed in your doctor’s office using topical and/or local anesthesia to numb your nose and sinuses. After numbing your nose, your doctor will introduce the SINUVA implant into your nostril at the end of a delivery system, and place the implant within your sinus. SINUVA usually cannot be felt once it is in place.
Typically, the procedure takes 30-40 minutes. This includes 10-30 minutes to numb your nose and around 5-10 minutes to place the SINUVA implant.
SINUVA is implanted in your sinus cavity next to the nasal polyps to provide local delivery of a drug called mometasone furoate (a type of steroid). The implant has been shown to be effective in reducing nasal obstruction and congestion and shrinking polyps.
SINUVA Sinus Implant: How It Works Video
If you are interested in the SINUVA Sinus Implant as an in-office treatment for recurrent nasal polyps, call CT Sinus Center at (203) 574-5997 to schedule a consultation. You may also request an appointment online.
Your doctor will always be evaluating your condition for the right treatment option. Explore if SINUVA is right for you. Express your desire for an alternative to surgery and current treatment options. Here are a few questions you can use to get the conversation started:
By asking questions and starting a conversation, you’ll be helping your doctor plan the right treatment for you.
The most common adverse reactions observed in clinical studies were bronchitis, nasopharyngitis, upper respiratory or middle ear infection, headache, lightheadedness, asthma, and nose bleed.
Patients experiencing excessive nasal bleeding, symptoms of infection or symptoms suggesting that the implant has moved, such as irritation or a choking sensation in the back of the throat, should immediately contact a healthcare professional.
Close monitoring is recommended if patients have a change of vision or a history of increased intraocular pressure, glaucoma, and/or cataracts.
As with all endoscopic sinus procedures, there are risks associated with the insertion and removal of SINUVA Sinus Implant. For that reason, SINUVA should only be inserted by physicians trained in Otolaryngology.
The placement-related risks include nose bleed, injuries to blood vessels, and bacterial infection.
Based on the results of the two clinical trials, the most common side effects were asthma, headache, and nose bleed.
Because SINUVA is placed directly amongst the nasal polyps, it is able to provide sustained symptom relief with a low rate of side effects. The safety of SINUVA was established in 400 patients in two clinical trials.
